Important Note Regarding the September 11, 2017 Press Release Announcing Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
You are now leaving Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.